Trials / Unknown
UnknownNCT02907606
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.
Detailed description
Liquid biopsy, specifically through the assessment of circulating tumor DNA(ctDNA) from peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic monitoring. Urinary samples are completely non-invasive and easily obtainable compared to blood and tissue extraction. To date, only a limited number of published studies have examined the feasibility of ctDNA detection from urine. This study will collect tumor tissues, pretreatment peripheral blood samples and urine samples from different TNM stages of NSCLC patients, and detect EGFR gene mutations in paired samples.
Conditions
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-06-01
- Completion
- 2020-08-01
- First posted
- 2016-09-20
- Last updated
- 2016-09-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02907606. Inclusion in this directory is not an endorsement.